References of "Bruyère, Olivier"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailRelief in mild-to-moderate pain is not a confounder in joint space narrowing assessment of full extension knee radiographs in recent osteoarthritis structure modifying drug trials
Pavelka, K.; Bruyère, Olivier ULg; Rovati, Lucio C et al

in Osteoporosis International (2003, November), 14(Suppl. 7), 62-63

Detailed reference viewed: 2 (0 ULg)
Full Text
Peer Reviewed
See detailControlled whole body vibration to decrease fall risk and improve health related quality of life in elderly patients
Bruyère, Olivier ULg; Wuidart, M. A.; di Palma, E. et al

in Osteoporosis International (2003, November), 14(Suppl. 7), 63

Detailed reference viewed: 22 (8 ULg)
Full Text
Peer Reviewed
See detailEvaluation of the osteoporosis self-assessment tool (OST) as a screening test for osteoporosis and osteopenia in men
De Ceulaer, F.; Hanssens, L.; Tancredi, Annalisa ULg et al

in Osteoporosis International (2003, November), 14(Suppl. 7), 93

Detailed reference viewed: 5 (0 ULg)
Full Text
Peer Reviewed
See detailEvaluation of prevalence of osteoporosis and osteopenia in men presenting at multiple risk detection campaign
Hanssens, L.; De Ceulaer, F.; Tancredi, Annalisa ULg et al

in Osteoporosis International (2003, November), 14(Suppl. 7), 90

Detailed reference viewed: 7 (2 ULg)
Full Text
Peer Reviewed
See detailEvaluation of a campaign for osteoporosis screening in the general population: what is the follow-up given by general practitioners to a positive screening result?
Richy, Florent; Pire, G.; Maassen, P. et al

in Osteoporosis International (2003, November), 14(Suppl. 7), 67

Detailed reference viewed: 1 (0 ULg)
Full Text
Peer Reviewed
See detailFive-year follow-up patients issued from a previous 3-year randomised, controlled trial of glucosamine sulfate in knee osteoarthritis
Bruyère, Olivier ULg; Compère, S.; Gathy, C. et al

in Osteoporosis International (2003, November), 14(Suppl 7), 9

Detailed reference viewed: 14 (4 ULg)
Full Text
Peer Reviewed
See detailEvaluation of an osteoporosis screening campaign in the general population: does misclassification by screening test impact on the perception of the campaign?
Richy, Florent; Pire, G.; Maassen, P. et al

in Osteoporosis International (2003, November), 14(Suppl. 7), 68

Detailed reference viewed: 10 (2 ULg)
See detailLong term clinical experience with glucosamine sulfate long-term clinical trials
Bruyère, Olivier ULg

Conference (2003, October 18)

Detailed reference viewed: 3 (0 ULg)
Full Text
Peer Reviewed
See detailFive-year follow-up of patients from a previous 3-year randomised, controlled trial of glucosamine sulfate in knee osteoarthritis
Bruyère, Olivier ULg; Compere, S.; Rovati, Lucio C et al

in Osteoarthritis and Cartilage (2003, October), 11(Suppl.1), 10-11

Detailed reference viewed: 17 (1 ULg)
Full Text
Peer Reviewed
See detailRelief in mild-to-moderate pain is not a confounder in joint space narrowing assessment of full extension knee radiographs in recent osteoarthritis structure-modifying drug trials
Pavelka, K.; Bruyère, Olivier ULg; Rovati, Lucio C et al

in Osteoarthritis and Cartilage (2003), 11(10), 730-737

Objective: To assess whether improvement in knee pain biased the determination of the structure-modifying effect reported for glucosamine sulfate in two recent 3-year, randomised, placebo-controlled ... [more ▼]

Objective: To assess whether improvement in knee pain biased the determination of the structure-modifying effect reported for glucosamine sulfate in two recent 3-year, randomised, placebo-controlled clinical trials, in which conventional standing antero-posterior full extension knee radiographs were used for the measurement of joint space narrowing, and in which pain relief might have improved knee full extension. Design: Patients completing the 3-year treatment course were selected based on a WOMAC pain decrease at least equal to the mean improvement in the glucosamine sulfate arms in either of the original studies, irrespective of treatment with glucosamine sulfate or placebo (drug responders or placebo responders). In a second approach, 3-year completers were selected if their baseline standing knee pain (item #5 of the WOMAC pain scale) was 'severe' or 'extreme' and improved by any degree at the end of the trials. In both cases, changes in minimum joint space width were compared between treatment groups. Results: Global knee pain was rnild-to-moderate in the two study populations and in all patient subsets identified. There were obviously more pain improvers in the glucosamine sulfate subsets (N=76 in the two studies combined) than in the placebo subsets (N=57), but WOMAC pain scores improved to the same extent, which was as large as over 50% relative to baseline. Nevertheless, the placebo subsets in both studies underwent an evident mean (SD) joint space narrowing, which in the pooled analysis of both studies was -0.22 (0.80) mm, and was not observed with glucosamine sulfate: +0.15 (0.60) mm (P=0.003 vs placebo). Similar results were found in the smaller subsets with greater than or equal to severe baseline standing knee pain that improved after 3 years, with a joint space narrowing nevertheless of -0.28 (0.76) mm with placebo (N=26), not observed with glucosamine sulfate: +0.21 (0.68) mm (N=31; P=0.014 vs placebo). Conclusions: Knee pain relief did not bias the report of a structure-modifying effect of glucosamine sulfate in two recent long-term trials using conventional standing antero-posterior radiographs, possibly due to the mild-to-moderate patient characteristics. (C) 2003 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved. [less ▲]

Detailed reference viewed: 33 (2 ULg)
See detailLes pathologies osteo-articulaires : approche pluridisciplinaire
Bruyère, Olivier ULg

Scientific conference (2003, September 11)

Detailed reference viewed: 3 (2 ULg)
Full Text
Peer Reviewed
See detailStructural and symptomatic efficacy of glucosamine and chondroitine sulfate in osteoarthritis: a comprehensive meta-analysis
Richy, Florent Y; Bruyère, Olivier ULg; Ethgen, Olivier ULg et al

in Arthritis and Rheumatism (2003, September), 48(number 9 (suppl.)), 214

Detailed reference viewed: 17 (2 ULg)
Full Text
Peer Reviewed
See detailFive-year follow-up of patients from a previous 3-year randomised, controlled trial of glucosamine sulfate in knee osteoarthritis
Bruyère, Olivier ULg; Compere, Stephanie; Rovati, Lucio C et al

in Arthritis and Rheumatism (2003, September), 48(number 9 (suppl.)), 80

Detailed reference viewed: 24 (0 ULg)
Full Text
Peer Reviewed
See detailControlled whole body vibrations improve health related quality of life in elderly patients
Bruyère, Olivier ULg; Wuidart, Marc-Antoine; Di Palma, Elio et al

in Arthritis and Rheumatism (2003, September), 48(9, Suppl. S), 502

Detailed reference viewed: 68 (9 ULg)
Full Text
Peer Reviewed
See detailNaturocetic (glucosamine and chondroitin sulfate) compounds as structure-modifying drugs in the treatment of osteoarthritis
Reginster, Jean-Yves ULg; Bruyère, Olivier ULg; Lecart, Marie-Paule ULg et al

in Current Opinion in Rheumatology (2003), 15

Purpose of review Several entities have been investigated carefully for the symptomatic and structural management of osteoarthritis. This review reports recent findings suggesting that such compounds may ... [more ▼]

Purpose of review Several entities have been investigated carefully for the symptomatic and structural management of osteoarthritis. This review reports recent findings suggesting that such compounds may delay the structural progression of osteoarthritis. Recent findings The most compelling evidence of a potential for inhibiting the structural progression of osteoarthritis has been obtained with glucosamine sulfate, whereas preliminary results obtained in patients with osteoarthritis of the hands also suggest that chondroitin sulfate could be used in the same indication. At any rate, these two compounds have clearly demonstrated a symptomatic action, mainly in osteoarthritis of the lower limbs. Patients with the less severe radiographic osteoarthritis will experience, in the long run, the most dramatic disease progression in terms of joint space narrowing. Such patients may be particularly responsive to structure-modifying drugs. Summary Glucosamine sulfate has demonstrated its ability to reduce the progression of osteoarthritis in the lower limbs. The preliminary results obtained in the hands suggest that chondroitin sulfate could also be of interest in this indication. An important issue is that all the conclusive studies with such chemical entities resulted from the use of prescription medicines, not over-the-counter pills or food supplements. [less ▲]

Detailed reference viewed: 30 (8 ULg)
Full Text
Peer Reviewed
See detailNew perspectives in the management of osteoarthritis. Structure modification: Facts or fantasy?
Reginster, Jean-Yves ULg; Bruyère, Olivier ULg; Henrotin, Yves ULg

in Journal of Rheumatology. Supplement (2003), 67(Suppl. 67), 14-20

Several entities have been carefully investigated for the symptomatic and structural management of osteoarthritis (OA). The most compelling evidence of a potential for inhibiting the structural ... [more ▼]

Several entities have been carefully investigated for the symptomatic and structural management of osteoarthritis (OA). The most compelling evidence of a potential for inhibiting the structural progression of OA has been obtained with glucosamine sulfate, while some preliminary results also suggest that other compounds could be used in the same indication. At any rate, several medications have clearly demonstrated a symptomatic action, mainly in OA of the lower limbs, including pain relief and improvement of functional disability. An important issue is that all conclusive studies with such chemical entities resulted from the use of prescription medicines and not over-the-counter or nutriceutical supplements. [less ▲]

Detailed reference viewed: 7 (1 ULg)
Full Text
Peer Reviewed
See detailStructural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis - A comprehensive meta-analysis
Richy, Florent; Bruyère, Olivier ULg; Ethgen, Olivier ULg et al

in Archives of Internal Medicine (2003), 163(13), 1514-1522

Objective: To assess the structural and symptomatic efficacy of oral glucosamine sulfate and chondroitin sulfate in knee osteoarthritis through independent meta-analyses of their effects on joint space ... [more ▼]

Objective: To assess the structural and symptomatic efficacy of oral glucosamine sulfate and chondroitin sulfate in knee osteoarthritis through independent meta-analyses of their effects on joint space narrowing, Lequesne Index, Western Ontario MacMaster University Osteoarthritis Index (WOMAC), visual analog scale for pain, mobility, safety, and response to treatment. Methods: An exhaustive systematic research of randomized, placebo-controlled clinical trials published or performed between January 1980 and March 2002 that assessed the efficacy of oral glucosamine or chondroitin on gonarthrosis was performed using MEDLINE, PREMEDLINE, EMBASE, Cochrane Database of Systematic Reviews, Current Contents, BIOSIS Previews, Health-STAR, EBM Reviews, manual review of the literature and congressional abstracts, and direct contact with the authors and manufacturers of glucosamine and chondroitin. Inclusion, quality scoring, and data abstraction were performed systematically by 2 independent reviewers who were blinded to sources and authors. Conservative approaches were used for clear assessment of potential efficacy. Results: Our results demonstrated a highly significant efficacy of glucosamine on all outcomes, including joint space narrowing and WOMAC. Chondroitin was found to be effective on Lequesne Index, visual analog scale pain, mobility, and responding status. Safety was excellent for both compounds. Conclusions: Our study demonstrates the structural efficacy of glucosamine and indistinguishable symptomatic efficacies for both compounds. Regarding the relatively sparse data on glucosamine and joint space narrowing and the absence of data on structural effects of chondroitin, further studies are needed to investigate the relationship among time, dose, patient baseline characteristics, and structural efficacy for an accurate, disease-modifying characterization of these 2 compounds. [less ▲]

Detailed reference viewed: 19 (6 ULg)
Full Text
Peer Reviewed
See detailBiochemical markers of bone and cartilage remodeling in prediction of longterm progression of knee osteoarthritis
Bruyère, Olivier ULg; COLLETTE, Julien ULg; Ethgen, Olivier ULg et al

in Journal of Rheumatology (2003), 30(5), 1043-50

OBJECTIVE: To investigate the relationship between biochemical markers of bone and cartilage remodeling and severity or progression (symptoms and structure) of knee osteoarthritis (OA). METHODS: Mean and ... [more ▼]

OBJECTIVE: To investigate the relationship between biochemical markers of bone and cartilage remodeling and severity or progression (symptoms and structure) of knee osteoarthritis (OA). METHODS: Mean and minimal joint space width (JSW) of the femorotibial joint were measured from standardized radiographs taken at baseline and at the end of a 3-year longitudinal study of patients with knee OA. Pain, stiffness, and physical function subscales of the Western Ontario and McMaster Universities Osteoarthritis (WOMAC) index were assessed at the same time points. Biochemical markers [serum keratan sulfate (KS), serum hyaluronic acid (HA), urine pyridinoline (PYD) and deoxypyridinoline (DPD), serum osteocalcin (OC), cartilage oligomeric matrix protein (COMP)] were assessed at baseline and after 1 year. RESULTS: At baseline, no significant correlations were observed between values of biochemical markers and JSW or any of the WOMAC scores. Baseline markers were not correlated with 3-year percentage changes observed in mean or minimal JSW and WOMAC scores. Changes observed after 1 year in OC and HA were significantly correlated with 3-year progression in mean JSW (r = -0.24, p = 0.04 and r = 0.27, p = 0.02, respectively) and in minimal JSW (r = -0.31, p = 0.01 and r = 0.24, p = 0.04, respectively). In patients from the lowest quartile of 1-year changes in HA (< -21.22 ng/ml), mean JSW decreased after 3 years by 0.76 (1.23) mm compared to an increase of 0.11 (0.83) mm in patients in the highest quartile (> +14.34 ng/ml) (p = 0.03). CONCLUSION: The 3-year radiological progression of knee OA could be predicted by a 1-year increase in OC or a 1-year decrease in HA levels. [less ▲]

Detailed reference viewed: 12 (5 ULg)
Full Text
Peer Reviewed
See detailSubchondral tibial bone mineral density predicts future joint space narrowing at the medial femoro-tibial compartment in patients with knee osteoarthritis
Bruyère, Olivier ULg; Dardenne, Charles-Bernard ULg; Lejeune, Eric ULg et al

in BONE (2003), 32(5), 541-545

Preliminary studies have shown that dual-energy X-ray absorptiometry (DXA) produces images of sufficient quality for a precise and accurate measurement at density of the subchondral bone. The objective of ... [more ▼]

Preliminary studies have shown that dual-energy X-ray absorptiometry (DXA) produces images of sufficient quality for a precise and accurate measurement at density of the subchondral bone. The objective of this study was to investigate the relationship between baseline subchondral tibial bone mineral density (BMD) and joint space narrowing observed after 1 year at the medial femoro-tibial compartment of the knee joint. Fifty-six consecutive patients, from both genders, with knee osteoarthritis diagnosed according to the American College of Rheumatology criteria, were included in the study. Radiographic posteroanterior views were taken, at baseline and after 1 year of follow-up. Minimum joint space width (JSW) measurement, at the medial femoro-tibial joint, was performed with a 0.1-mm graduated magnifying lens. Baseline BMD of the subchondral tibial bone was assessed by DXA. The mean +/- SD age of the patients was 65.3 +/- 8.7 years, with a body mass index of 28.0 +/- 4.9 kg/m(2). The minimum JSW was 3.5 +/- 1.5 mm and the mean BMD of the subchondral bone was 0.848 +/- 0.173 g/cm(2). There was a significant negative correlation between subchondral BMD and 1-year changes in minimum JSW (r = -0.43, p = 0.02). When performing a multiple regression analysis with age, sex, body mass index, and minimum JSW at baseline as concomitant variables, BMD of the subchondral bone as well as JSW at baseline were independent predictors of 1-year changes in JSW (p = 0.02 and p = 0.005, respectively). Patients in the lowest quartile of baseline BMD (<0.73 g/cm(2)) experienced less joint space narrowing than those in the highest BMD quartile (>0.96 g/cm(2)) (+0.61 +/- 0.69 turn versus -0.13 +/- 0.27 mm; p = 0.03). Assessment of BMD of the subchondral tibial bone is significantly correlated with future joint space narrowing and could be used as a predictor of knee osteoarthritis progression. (C) 2003 Elsevier Science (USA). All rights reserved. [less ▲]

Detailed reference viewed: 54 (5 ULg)